Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

There was variation seen in coverage by jurisdiction and demographic characteristics, with younger adults and those without health insurance having the lowest coverage. (HealthDay News) — COVID-19, ...

The researchers found that postpartum depression prevalence doubled during the study period, increasing from 9.4% in 2010 to 19.0% in 2021. (HealthDay News) — Diagnosis of postpartum depression ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment ...

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

(HealthDay News) — More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the American ...

Credit: Endo, Inc At this time, there have been no reports of adverse events related to this recall. While the blister strips ...

In three databases, 4.5, 6.0, and 6.2 percent of medically attended RSV patients experienced 28-day all-cause hospitalization ...